Senate Finance chair to CMS: How can Alzheimer's patients access new mAbs

Zachary Brennan

Senior Editor

Senate Finance Committee Chair Ron Wyden (D-OR) sent a stern letter to CMS this week, calling on the centers “to provide prompt, clear, and publicly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Senate Finance chair to CMS: How can Alzheimer's patients access new mAbs

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Former FDA chief calls job cuts ‘haphazard, poorly thought-out’

NIH payment cuts are 'reasoned and rational,' government says

Novo looks to recoup $830M from hypertension drug partner, claiming fraud

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sen­ate Fi­nance chair to CMS: How can Alzheimer's pa­tients ac­cess new mAbs

Zachary Brennan

Senior Editor

Sign up to read this article for free.

For­mer FDA chief calls job cuts ‘hap­haz­ard, poor­ly thought-out’

NIH pay­ment cuts are 'rea­soned and ra­tio­nal,' gov­ern­ment says

No­vo looks to re­coup $830M from hy­per­ten­sion drug part­ner, claim­ing fraud

Af­ter re­search piv­ot, Bio­gen beefs up pipeline with Stoke's late-stage Dravet can­di­date

As part of turn­around, Sol­id Bio re­ports promis­ing ini­tial da­ta for Duchenne gene ther­a­py

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Senate Finance chair to CMS: How can Alzheimer's patients access new mAbs

Former FDA chief calls job cuts ‘haphazard, poorly thought-out’

NIH payment cuts are 'reasoned and rational,' government says

Novo looks to recoup $830M from hypertension drug partner, claiming fraud

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence